Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
- Study HIC#:2000023073REG
- Last Updated:07/15/2021
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
- Age2 years - 21 years
- Start Date07/25/2018
- End Date06/30/2028
Trial Purpose and Description
1. Prospectively collect essential data from children, adolescents and young adults with pediatric onset rheumatic diseases.
2. Evaluate the safety of therapeutic agents in persons with pediatric onset rheumatic diseases.
Children with pediatric rheumatic diseases enrolled from participating CARRA sites.
1.Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases (see appendix A).
2.Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures.
3.Subject and/or parent/legal guardian can read either English or Spanish.
4.Subject and/or parent/legal guardian is willing to be contacted in the future by study staff.
1. Greater than 21 years of age at the time of enrollment.